Seguici
IT
IT

Uno degli obiettivi principali di Life4me+ è quello di prevenire nuovi casi di HIV e altre infezioni sessualmente trasmissibili, epatite C e tubercolosi.

L'app aiuta a stabilire una comunicazione anonima tra i medici e le persone sieropositive. Ti consente di organizzare comodamente l'orario di assunzione dei farmaci e di impostare promemoria nascosti e personalizzati.

Tutte le notizie / Aprile 2017

Archivio

✕
25 aprile 2017
4077
Life4me+ EE App Starts in Estonia – A Meeting With Healthcare Leaders In Tallinn

Life4me+ EE App Starts in Estonia – A Meeting With Healthcare Leaders In Tallinn

A meeting between the Life4me+ EE team and the leaders of the Estonian National Institute for Health Development was held in Tallinn yesterday. The Life4me+ EE sales director in the Baltic region Alexander Tamm received ideas and comments from Institute's representatives ...
24 aprile 2017
3902
97% Cures of Genotype 3 Hep C In Glecaprevir and Pibrentasvir Combination

97% Cures of Genotype 3 Hep C In Glecaprevir and Pibrentasvir Combination

#AbbVie’s pangenotypic direct-acting antiviral combination of two drugs — glecaprevir and pibrentasvir — cured 97% of people with early-stage genotype 3 hepatitis C virus (HCV), the hardest genotype to treat, according to results of the ENDURANCE-3 trial presented at the ...
24 aprile 2017
4552
One vs. Many: The Accuracy Of HIV Rapid Diagnostic Tests

One vs. Many: The Accuracy Of HIV Rapid Diagnostic Tests

Médecins Sans Frontières (MSF) has carried out an assessment of the HIV tests accuracy in five sub-Saharan African countries confirming the necessity to accurately choose multiple HIV rapid diagnostic tests in an algorithm/sequence for performing an HIV diagnosis.
24 aprile 2017
3934
Estonian version of Life4me+ EE App for HIV-positive persons

Estonian version of Life4me+ EE App for HIV-positive persons

Life4me+ team releases the Estonian version of its App for HIV-positive persons translated to the Estonian language
21 aprile 2017
3735
Defective HIV Proviruses Prevent Immune Possible Cure, John Hopkins Scientists Suggest

Defective HIV Proviruses Prevent Immune Possible Cure, John Hopkins Scientists Suggest

Proteins created by broken forms of HIV previously believed to be harmless interact with the immune system and are actively controlled by a particular type of immune cell, called cytotoxic T-cells, researchers at Johns Hopkins and George Washington universities report a ...
21 aprile 2017
8470
First HIV PEP/PrEP Centre In Europe Is To Open In Barcelona

First HIV PEP/PrEP Centre In Europe Is To Open In Barcelona

The First in Europe PEP/PrEP Center will be opened in September 2017. Barcelona Checkpoint has initiated the construction of the Center to be named ’Barcelona PrEPPoint,’ the primary purpose of which will be the popularization of pre- and post-exposure prophylaxis for HIV — ...
21 aprile 2017
3628
Burkitt’s HIV-associated Lymphoma — Mechanism Of The Development Revealed

Burkitt’s HIV-associated Lymphoma — Mechanism Of The Development Revealed

The risk of developing Burkitt's lymphoma is extremely high at the terminal stages of HIV according to the results of a Russian study conducted by a group of scientists from the MSU's A.N. Belozersky Research Institute of Physico-Chemical Biology.
20 aprile 2017
3684
Restaurant Fundraising Helps People With HIV/AIDS

Restaurant Fundraising Helps People With HIV/AIDS

Thursday is “Dining Out For Life.” If you live in the U. S. or Canada you can help fund services for people with HIV and AIDS simply by going out to dinner.
19 aprile 2017
3801
New Study Of Cabotegravir As Injectable HIV Medication Started

New Study Of Cabotegravir As Injectable HIV Medication Started

A study to evaluate whether a new injectable medication cabotegravir can work as well as an existing oral pill to protect safely against HIV among men who have sex with men and transgender women who have sex with men launched by The HIV Prevention Trials Network.
19 aprile 2017
3770
PrEP For Injection Drug Users: Bangkok Tenofovir Study

PrEP For Injection Drug Users: Bangkok Tenofovir Study

People who inject drugs are likely to choose PrEP, according to the Bangkok Tenofovir Study report in The Lancet HIV April issue.
Utilizziamo i cookie su questo sito per migliorare la tua esperienza.
Facendo clic su qualsiasi pulsante di questo sito Web, dai il tuo consenso per l'impostazione dei cookie.